| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Bezisterim | HE-3286; NE-3107 | Phase 3 Clinical | Harbor Therapeutics, Biovie Inc | Diabetes Mellitus, Type 2; Brain Injuries, Traumatic; Insulin Resistance; Arthritis, Rheumatoid; Post-Acute COVID-19 Syndrome; Alzheimer Disease; Colitis, Ulcerative; Parkinson Disease | Details |
| PN-235 | JNJ-77242113; PN-235; JNJ-2113; PN-21235; JNJ-77242113-AAC | Phase 3 Clinical | Protagonist Therapeutics Inc | Psoriasis; Colitis, Ulcerative; Plaque psoriasis | Details |
| PN-232 | PN-232; JNJ75105186 | Phase 1 Clinical | Protagonist Therapeutics Inc | Details |
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Ustekinumab biosimilar (Samsung Bioepis) | SB-17; SB17 | Approved | Samsung Bioepis Co Ltd | Pyzchiva | EU | Crohn Disease; Colitis, Ulcerative | Samsung Bioepis Nl Bv | 2024-04-19 | Gastrointestinal Diseases; Skin Diseases; Psoriasis; Arthritis, Psoriatic; Rheumatic Diseases; Colitis, Ulcerative; Inflammation; Crohn Disease; Plaque psoriasis | Details |

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)
メールアドレス
order.jp@acrobiosystems.com
アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8



